ATE188966T1 - 1,2,4 - triazolo(1,5-a)pyrimidine und ihre verwendung bei der behandlung von neurologischen erkrankungen - Google Patents

1,2,4 - triazolo(1,5-a)pyrimidine und ihre verwendung bei der behandlung von neurologischen erkrankungen

Info

Publication number
ATE188966T1
ATE188966T1 AT94929537T AT94929537T ATE188966T1 AT E188966 T1 ATE188966 T1 AT E188966T1 AT 94929537 T AT94929537 T AT 94929537T AT 94929537 T AT94929537 T AT 94929537T AT E188966 T1 ATE188966 T1 AT E188966T1
Authority
AT
Austria
Prior art keywords
alkyl
halo
cyano
hydroxy
optionally substituted
Prior art date
Application number
AT94929537T
Other languages
German (de)
English (en)
Inventor
David J Heal
Fernandez Maria Isab Fernandez
Bruce G Sargent
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag filed Critical Knoll Ag
Application granted granted Critical
Publication of ATE188966T1 publication Critical patent/ATE188966T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
AT94929537T 1993-10-13 1994-10-12 1,2,4 - triazolo(1,5-a)pyrimidine und ihre verwendung bei der behandlung von neurologischen erkrankungen ATE188966T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939321162A GB9321162D0 (en) 1993-10-13 1993-10-13 Therapeutic agents
PCT/EP1994/003364 WO1995010521A1 (en) 1993-10-13 1994-10-12 Therapeutic agents

Publications (1)

Publication Number Publication Date
ATE188966T1 true ATE188966T1 (de) 2000-02-15

Family

ID=10743505

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94929537T ATE188966T1 (de) 1993-10-13 1994-10-12 1,2,4 - triazolo(1,5-a)pyrimidine und ihre verwendung bei der behandlung von neurologischen erkrankungen

Country Status (31)

Country Link
US (1) US5753665A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0723546B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH09503771A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1040537C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE188966T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU679573B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG62405B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9407812A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2173857A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ106996A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69422724T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0723546T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2142413T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI961630A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB9321162D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3032480T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUT74580A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL111259A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN179169B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY112110A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO306509B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ274500A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL177920B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT723546E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RO (1) RO117020B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2136684C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK282329B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW372237B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA42738C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1995010521A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA947949B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506382D0 (en) * 1995-03-29 1995-05-17 Boots Co Plc Pharmaceutical compositions
GB9507348D0 (en) * 1995-04-08 1995-05-31 Knoll Ag Therapeutic agents
US5714607A (en) * 1995-12-01 1998-02-03 American Cyanamid Company Process improvement in the synthesis of N- 3-(3-cyano-pyrazolo 1,5-a!pyrimidin-7-yl)phenyl!-N-ethylacetamide
CZ18199A3 (cs) 1996-07-25 1999-06-16 Merck Sharp And Dohme Limited Triazolopyridazinové deriváty, způsob výroby a farmaceutický prostředek
GB9617727D0 (en) 1996-08-23 1996-10-02 Knoll Ag Process
GB9626746D0 (en) * 1996-12-23 1997-02-12 Knoll Ag Process
DE19706337A1 (de) * 1997-02-19 1998-08-20 Basf Ag Verfahren zur Herstellung von enantiomerenreinen Estern
DE19706336A1 (de) * 1997-02-19 1998-08-20 Basf Ag Verfahren zur Herstellung von enantiomerenreinen Alkoholen
DE19707008A1 (de) * 1997-02-21 1998-08-27 Basf Ag Verfahren zur Herstellung von enantiomerenreinen Alkoholen
AU760688B2 (en) * 1998-10-16 2003-05-22 Merck Sharp & Dohme Limited Pyrazolo-triazine derivatives as ligands for GABA receptors
GB9906126D0 (en) * 1999-03-18 1999-05-12 Knoll Ag Pharmaceutical formulations
GB9906124D0 (en) * 1999-03-18 1999-05-12 Knoll Ag Therapeutic agent
GB9906130D0 (en) * 1999-03-18 1999-05-12 Knoll Ag Compounds for use in therapy
GB9914743D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
HK1052646A1 (zh) * 2000-06-30 2003-09-26 Wyeth 替代三氮苯(triazolopyrimidines)作为抗癌剂
TWI334868B (en) * 2003-06-03 2010-12-21 Nippon Kayaku Kk [1,2,4] triazoro [1,5-a] pyrimidine-2-ylurea derivative and use thereof
WO2005080320A1 (en) 2004-02-13 2005-09-01 Warner-Lambert Company Llc Androgen receptor modulators
EP1737813A1 (en) 2004-04-13 2007-01-03 Warner-Lambert Company LLC Androgen modulators
BRPI0509980A (pt) 2004-04-22 2007-10-16 Warner Lambert Co moduladores de androgênio
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
PL2328414T3 (pl) 2008-08-29 2014-05-30 Concert Pharmaceuticals Inc Podstawione pochodne triazolo-pirydazyny
EP2414364A1 (en) * 2009-04-01 2012-02-08 NeuroSearch A/S SUBSTITUTED Ý1,2,4¨TRIAZOLOÝ1,5-a¨PYRIMIDINES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS
US8685987B2 (en) 2009-04-01 2014-04-01 Ataxion, Inc. Substituted [1,2,4]triazolo[1,5-a]pyrimidines and their use as potassium channel modulators
WO2010112486A1 (en) * 2009-04-01 2010-10-07 Neurosearch A/S SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS
WO2020231723A1 (en) 2019-05-13 2020-11-19 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE46306B1 (en) * 1977-02-11 1983-05-04 Ici Ltd Safeguarded toxic chemical compositions containing an emetic
FR2549834B1 (fr) * 1983-07-25 1985-10-18 Sanofi Sa Derives de triazolo-pyrimidine, leur procede de preparation et leur application therapeutique en tant que tonicardiaques
WO1989001478A1 (en) * 1987-08-07 1989-02-23 The Australian National University ARYLOXY- AND ARALKYLTHIO-IMIDAZO[1,2-b]PYRIDAZINES
US5387747A (en) * 1992-02-24 1995-02-07 Laboratoires Upsa Triazolopyrimidine derivatives which are angiotensin II receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present

Also Published As

Publication number Publication date
PL177920B1 (pl) 2000-01-31
DE69422724T2 (de) 2000-09-07
FI961630A0 (fi) 1996-04-12
RU2136684C1 (ru) 1999-09-10
US5753665A (en) 1998-05-19
AU7855494A (en) 1995-05-04
WO1995010521A1 (en) 1995-04-20
IL111259A (en) 1998-02-08
MY112110A (en) 2001-04-30
HUT74580A (en) 1997-01-28
JPH09503771A (ja) 1997-04-15
BG100485A (bg) 1996-11-29
SK282329B6 (sk) 2002-01-07
BG62405B1 (bg) 1999-10-29
BR9407812A (pt) 1997-05-06
PL313970A1 (en) 1996-08-05
EP0723546A1 (en) 1996-07-31
NO961435D0 (no) 1996-04-11
UA42738C2 (uk) 2001-11-15
NO306509B1 (no) 1999-11-15
PT723546E (pt) 2000-04-28
ZA947949B (en) 1996-01-23
EP0723546B1 (en) 2000-01-19
RO117020B1 (ro) 2001-09-28
DE69422724D1 (de) 2000-02-24
CZ106996A3 (en) 1996-09-11
GR3032480T3 (en) 2000-05-31
IN179169B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-09-06
IL111259A0 (en) 1995-03-30
NO961435L (no) 1996-06-10
NZ274500A (en) 1997-06-24
CN1135754A (zh) 1996-11-13
ES2142413T3 (es) 2000-04-16
GB9321162D0 (en) 1993-12-01
HU9600959D0 (en) 1996-06-28
SK43796A3 (en) 1996-10-02
CN1040537C (zh) 1998-11-04
CA2173857A1 (en) 1995-04-20
FI961630A7 (fi) 1996-04-12
DK0723546T3 (da) 2000-05-01
AU679573B2 (en) 1997-07-03
TW372237B (en) 1999-10-21

Similar Documents

Publication Publication Date Title
ATE188966T1 (de) 1,2,4 - triazolo(1,5-a)pyrimidine und ihre verwendung bei der behandlung von neurologischen erkrankungen
ATE385238T1 (de) Verwendung von dpiv-inhibitoren als therapeutika für krankhafte neurologische zustände
EP0636025A4 (en) Compounds useful for treating allergic or inflammatory diseases.
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
DE59710417D1 (de) N-7 HETEROCYCLYL-PYRROLO[ 2,3-d]PYRIMIDINE UND IHRE VERWENDUNG
CA2119511A1 (en) Benzimidazole compounds, their use and preparation
NZ539841A (en) Hydroxyethylamine derivatives for the treatment of alzheimer's disease
ZA9410339B (en) Diazabicyclic neurokinin antagonists
GEP20033029B (en) Substituted 1,8-Naphthyridin-4(1H)-Ones as Phosphodiesterase 4 Inhibitors
NO951797L (no) Terapeutiske midler
PL313941A1 (en) Alkoxyalkyl carbamates of imidazo /1,2-a/ pyrimidines
GB9418912D0 (en) Pharmaceutically active compounds
TW200726769A (en) Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates
BG108180A (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
AR032653A1 (es) Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos.
BG102080A (en) Amino acid derivatives of substituted quinoxalin 2,3-dion derivatives such as glutamate receptor antagonists
TW359667B (en) Tetralines
IL104478A (en) N-5-protected 2,5-diamino-4, 6-dichloropyrimidines and processes for their preparation
EP0489925A4 (en) Pyrimidine compound and pharmaceutically acceptable salt thereof
JO1833B1 (en) Therapeutic agents
MXPA01009384A (es) Composiciones farmaceuticas que comprenden un derivado de pirimidina y ciclodextrina.
SI0729469T1 (en) IMIDAZO (1,5-a)QUINOLINES FOR TREATMENT OF ANXIETY AND SLEEP DISORDERS

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee